Kainova Therapeutics doses first patient with cancer monotherapy
Kainova Therapeutics has dosed the first patient with its Treg-depleting monotherapy. The biopharmaceutical company dosed the patient in a Phase I/II clinical trial of DT-7012, a proprietary Treg depleting antiCCR8 monoclonal antibody, in patients with advanced solid tumours. The study is evaluating DT7012 as monotherapy… Read More